x

Posted 07 January, 2022

AVENUE THERAPEUTICS, INC. appointed new CEO

CEO Change detected for ticker OTC:ATXI in a 8-K filed on 07 January, 2022.


  On January 7, 2022 the Company's Board of Directors appointed Dr. Lucy Lu, M.D., the Company's President and Chief Executive Officer, as the Company's interim Chief Financial Offier and Principal Financial Officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of AVENUE THERAPEUTICS, INC.
Health Care/Life Sciences • Pharmaceuticals
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
Market Cap
$2.05M
View Company Details
AVENUE THERAPEUTICS, INC. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On January 5, 2022, Mr. Joseph Vazzano notified Avenue Therapeutics, Inc. (the "Company") that he was resigning from his role as the Company's Chief Financial Officer, effective January 14, 2022, to pursue other opportunities. Mr. Vazzano did not resign as a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.


In connection with Mr. Vazzano's resignation and transition to a consulting role, the Company entered into a consulting agreement with Mr. Vazzano dated January 7, 2022. 


On January 7, 2022 the Company's Board of Directors appointed Dr. Lucy Lu, M.D., the Company's President and Chief Executive Officer, as the Company's interim Chief Financial Offier and Principal Financial Officer.